文献速递药物不良反应与药物警戒

药物暴露后多发性硬化症发生的证据映射研究

Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.
PubMed 文献 · Drug Saf · 2017-01-01

该研究通过检索MEDLINE和Embase(截至2016年7月)并筛选832篇文章后纳入58篇文献,映射和评估药物暴露后多发性硬化症(MS)发生的证据。纳入文献包括30篇病例报告/系列、24项纵向研究和4项随机对照试验,半数聚焦免疫调节药物(依那西普、英夫利西单抗、阿达木单抗),提示与MS发生的关联,但证据强度低且结果矛盾。

要点

  • 免疫调节药物(依那西普、英夫利西单抗、阿达木单抗)的病例报告提示可能与MS发生相关。
  • 避孕药和抗菌药物的人群研究未得出一致结论。
  • 总体证据强度低且结果矛盾,需方法学进展以控制基础疾病的混杂作用。

核心结论

  • identified药物类别呈现异质性药理学特征。
  • 证据强度低且结果矛盾,凸显了解决药物在MS发生中可能作用的困难。
  • 需要方法学进展,特别是控制特定药物类别的基础疾病混杂作用。

研究设计与样本

  • 检索MEDLINE和Embase截至2016年7月的文献,筛选832篇文章后纳入58篇(其中14篇通过审查综述参考文献列表发现)。
  • 纳入文献包括30篇病例报告和病例系列、24项纵向研究和4项随机对照试验。
  • 使用纽卡斯尔-渥太华量表和ISPE及ISoP指南评估纳入研究质量。

主要发现

  • 7项纵向研究质量评分良好(至少7/9),而病例报告/系列存在多个局限性。
  • 半数纳入文章聚焦免疫调节药物(依那西普、英夫利西单抗和阿达木单抗),尤其在病例报告/系列中,提示与MS发生的关联。
  • 避孕药和抗菌药物在一些人群研究中被调查,但无明确结果。

局限性

  • 证据强度低且结果矛盾。
  • 病例报告/系列存在多个局限性。
  • 需要方法学进展以控制基础疾病的混杂作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of drugs in the occurrence of multiple sclerosis (MS) is perceived to be insufficiently investigated. OBJECTIVE: The aim of this study was to map and assess the evidence on MS occurrence after drug exposure, in order to identify possible signals of causal association. METHODS: A search strategy was performed in MEDLINE and Embase as of July 2016; references consistent with the aim of the study were analysed to extract relevant measures of causal association between drugs and MS. The Newcastle-Ottawa Scale and appropriate guidelines from the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) were used to assess the quality of included studies. RESULTS: After screening 832 articles, 58 were selected (of which 14 were found by checking the reference lists of reviews): 30 case reports and case series, 24 longitudinal studies and four randomized controlled trials. Seven longitudinal studies had good (at least 7 out of 9) quality scores, whereas case reports/case series presented several limitations. Half of included articles focused on immunomodulatory drugs (etanercept, infliximab and adalimumab), especially in case reports/series, suggesting an association with MS occurrence. Contraceptives and antibacterials were investigated in some population-based studies, without definite results. CONCLUSION: A heterogeneous pharmacological profile of identified classes emerged. Low strength of evidence and conflicting results highlighted the difficulties in addressing the possible contribution of drugs in MS occurrence. Methodological advances are needed, especially to control the confounding role of underlying disease for specific drug classes.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Antonazzo IC, Raschi E, Vignatelli L, et al. Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. Drug Saf. 2017. PMID: 28597251. doi:10.1007/s40264-017-0551-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。